SIM
FRX

Sentry Investment Management’s FOREST LABORATORIES INC FRX Stock Holding History

Sentry Investment Management’s Portfolio FRX Stock Details FRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-12,857
Closed -$1.27M – 544
2014
Q2 		$1.27M Sell
12,857
-943
-7% -$87.9K 0.07% 216
2014
Q1 		$1.27M Hold
13,800
– – 0.07% 211
2013
Q4 		$828K Sell
13,800
-16,500
-54% -$830K 0.04% 299
2013
Q3 		$1.3M Buy
30,300
+7,800
+35% +$339K 0.08% 195
2013
Q2 		$923K Buy
+22,500
New +$869K 0.05% 169

Other funds holding FRX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
CM
Castleark Management Chicago, Illinois $3.02B AUM 53.92% 1-Year Est. Return
OFG
OTA Financial Group Purchase, New York $143M AUM 16.9% 1-Year Est. Return
KRSITF
Kentucky Retirement Systems Insurance Trust Fund Frankfort, Kentucky $1.47B AUM 27.58% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $1.87B AUM 29.51% 1-Year Est. Return

Sentry Investment Management's FRX Position: Q3 2014 in Review

Sentry Investment Management sold out of FOREST LABORATORIES INC (FRX) in Q3 2014, closing a stake of 12,857 shares — an estimated $1.27M sold.

Sentry Investment Management first reported a position in FRX in Q2 2013 and held it in 5 quarters. The position peaked at $1.3M in Q3 2013. 5 funds tracked by Wall St. Rank hold FRX as of Q3 2014.

  • Sentry Investment Management reported no remaining FOREST LABORATORIES INC position as of Q3 2014 after selling out during the quarter.
  • Sentry Investment Management sold 12,857 FOREST LABORATORIES INC shares in Q3 2014, an estimated $1.27M.
  • Sentry Investment Management first reported a position in FOREST LABORATORIES INC in Q2 2013 and held it in 5 quarters.
  • Sentry Investment Management's FOREST LABORATORIES INC position peaked at $1.3M in Q3 2013.
  • 5 funds tracked by Wall St. Rank held FOREST LABORATORIES INC as of Q3 2014.

Based on Sentry Investment Management's 13F filing for Q3 2014, filed 13 Nov 2014.